登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《bioRxiv，6月14日，The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-06-19

  • The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2
    Melissa Zimniak, Luisa Kirschner, Helen Hilpert,  View ORCID ProfileJürgen Seibel,  View ORCID ProfileJochen Bodem
    doi: https://doi.org/10.1101/2020.06.14.150490

    Abstract
    To circumvent time-consuming clinical trials, testing whether existing drugs are effective inhibitors of SARS-CoV-2, has led to the discovery of Remdesivir. We decided to follow this path and screened approved medications “off-label” against SARS-CoV-2. In these screenings, Fluoxetine inhibited SARS-CoV-2 at a concentration of 0.8µg/ml significantly, and the EC50 was determined with 2.5ng/ml. Fluoxetine is a racemate consisting of both stereoisomers, while the S-form is the dominant serotonin reuptake inhibitor. We found that both isomers show similar activity on the virus. Fluoxetine treatment resulted in a decrease in viral protein expression. Furthermore, Fluoxetine inhibited neither Rabies virus, human respiratory syncytial virus replication nor the Human Herpesvirus 8 or Herpes simplex virus type 1 gene expression, indicating that it acts virus-specific. We see the role of Fluoxetine in the early treatment of SARS-CoV-2 infected patients of risk groups.

  • 原文来源：https://www.biorxiv.org/content/10.1101/2020.06.14.150490v1
27浏览量
原文链接
相关报告

  • 《bioRxiv，6月6日，Synthetic Antibodies neutralize SARS-CoV-2 infection of mammalian cells》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-06-09
    • Synthetic Antibodies neutralize SARS-CoV-2 infection of mammalian cells Shane Miersch, Mart Ustav, Zhijie Li, James B. Case, Safder Ganaie, Giulia Matusali, Francesca Colavita, Daniele Lapa, Maria R. Capobianchi, View ORCID ProfileGuiseppe Novelli, Jang B. Gupta, Suresh Jain, Pier Paolo Pandolfi, Michael S. Diamond, Gaya Amarasinghe, James M. Rini, Sachdev S. Sidhu doi: https://doi.org/10.1101/2020.06.05.137349 Abstract Coronaviruses (CoV) are a large family of enveloped, RNA viruses that circulate in mammals and birds but have crossed the species barrier to infect humans seven times. Of these, three pathogenic strains have caused zoonotic infections in humans that result in severe respiratory syndromes including the Middle East Respiratory Syndrome (MERS-CoV), severe acute respiratory syndrome (SARS-CoV), and now SARS-CoV-2 coronaviruses, the latter of which is the cause of the ongoing pandemic of coronavirus disease 2019 (COVID-19). Here, we describe a panel of synthetic monoclonal antibodies, built on a human framework, that bind SARS-CoV-2 spike protein, compete for binding with ACE2, and potently inhibit infection by SARS-CoV-2. These antibodies were found to have a range of neutralization potencies against live virus infection in Vero E6 cells, potently inhibiting authentic SARS-CoV-2 virus at sub-nanomolar concentrations. These antibodies represent strong immunotherapeutic candidates for treatment of COVID-19. Competing Interest Statement S.S, P.P.P and S.J, are cofounders of Virna Therapeutics. The company is developing novel therapies for COVID-19 and other viruses.
    147浏览量
    原文链接

  • 《bioRxiv，6月2日，An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-06-03
    • An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction View ORCID ProfileLeo Hanke, Maria Laura Perez Vidakovics, Daniel Sheward, Hrishikesh Das, Tim Schulte, Ainhoa Moliner Morro, Martin Corcoran, Adnane Achour,  View ORCID ProfileGunilla Karlsson Hedestam,  View ORCID ProfileB. Martin Hällberg, Ben Murrell,  View ORCID ProfileGerald M McInerney doi: https://doi.org/10.1101/2020.06.02.130161 Abstract We report the isolation and characterization of an alpaca-derived, single domain antibody fragment (nanobody) that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein (spike) and potently neutralizes the virus. A cryo-electron microscopy structure of the bound complex at 2.9 Å resolution reveals that the nanobody (Ty1) binds to an epitope on the RBD accessible in both the "up" and "down" conformations and that Ty1 sterically hinders RBD-ACE2 binding. Mechanistic characterization confirms that Ty1 directly interferes with host cell receptor binding. This 12.8 kDa nanobody binds the SARS-CoV-2 spike with high specificity and affinity, and can be produced in high quantities recombinantly thereby offering potential as a potent and widely accessible SARS-CoV-2 antiviral agent.
    133浏览量
    原文链接